Morgan Stanley lifts Fisher & Paykel stock rating to Overweight

Morgan Stanley upgraded Fisher & Paykel Healthcare to Overweight with a price target of NZD38.90 (up from NZD36.70), citing the company's FY25 results, FY26 guidance, and revised operational assumptions. The upgrade reflects a positive outlook on the company's earnings growth relative to variability, return on invested capital, and balance sheet strength, suggesting a potential 12% upside from the new price targets. While acknowledging high market multiples, Morgan Stanley views Fisher & Paykel Healthcare favorably compared to its industry peers.

Analysis

Morgan Stanley has upgraded Fisher & Paykel Healthcare (FPH) to Overweight from Equalweight, increasing its NZD price target to NZD38.90 from NZD36.70 and its AUD target to AUD35.90 from AUD34.00. The article reports that Stifel analysts cited FPH's fiscal year 2025 results, guidance for 2026, and revised operational assumptions as the basis for this upgrade by Morgan Stanley. These cited factors reportedly resulted in less than a 1% average earnings per share (EPS) revision through to FY28e, with approximately a 1% increase in outer years, suggesting the upgrade is not primarily driven by significantly altered earnings forecasts. Morgan Stanley's own positive view, underpinning the Overweight rating, is attributed to FPH's attractive earnings growth relative to its variability, its robust return on invested capital (ROIC), and the strength of its balance sheet. These characteristics are seen as positioning the company favorably against industry peers, even amidst high prevailing market multiples. The new price targets from Morgan Stanley imply a potential upside of approximately 12% for the stock. The article also notes that an external AI-driven analysis by InvestingPro did not identify FPH as a top-ranking undervalued stock.

Key Decisions for Investors

• Investors should note Morgan Stanley's Overweight rating and new price targets for Fisher & Paykel Healthcare, which suggest a potential 12% upside and reflect a positive outlook on the company's fundamentals relative to peers.
• The articulated strengths of Fisher & Paykel Healthcare, such as its earnings growth profile, return on invested capital, and balance sheet, warrant consideration, particularly given the company's favorable comparison within its industry despite high market multiples.
• Considering that the upgrade is based on modest EPS forecast revisions and that an alternative AI-based valuation tool did not flag the stock as a top pick for undervaluation, prudent investors may wish to conduct thorough due diligence to align this analyst upgrade with their own investment criteria and risk assessment.